Cargando…
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Autores principales: | Benatar, Michael, Wuu, Joanne, Andersen, Peter M., Bucelli, Robert C., Andrews, Jinsy A., Otto, Markus, Farahany, Nita A., Harrington, Elizabeth A., Chen, Weiping, Mitchell, Adele A., Ferguson, Toby, Chew, Sheena, Gedney, Liz, Oakley, Sue, Heo, Jeong, Chary, Sowmya, Fanning, Laura, Graham, Danielle, Sun, Peng, Liu, Yingying, Wong, Janice, Fradette, Stephanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606151/ https://www.ncbi.nlm.nih.gov/pubmed/36175782 http://dx.doi.org/10.1007/s13311-022-01286-9 |
Ejemplares similares
-
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
por: Benatar, Michael, et al.
Publicado: (2022) -
Tofersen: Silver Lining or Hyperbole??
por: Chawla, Tanushree, et al.
Publicado: (2023) -
T(2)-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS
por: Evans, Matthew C, et al.
Publicado: (2014) -
Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS
por: Benatar, Michael, et al.
Publicado: (2018) -
Neuroscience and behavioral genetics in US criminal law: an empirical analysis
por: Farahany, Nita A.
Publicado: (2016)